We’re pursuing our Orexin Receptor 2 Agonist Program to bring potentially transformative treatment options to patients with sleep-wake, neurological, neurodegenerative and psychiatric disorders.
We are leaders, innovators, and scientists aiming to pursue medicines that are transformational for patients.